关键词：亚太地区；药品；市场环境；市场趋势
摘 要：In the past six months, drug price cuts continued to reverberate across the Asia-Pacific. Major countries such as China, India and Australia announced further drug price reductions. Leading Asian drugmakers posted a mixed bag of earnings. Takeda Pharmaceutical (TSE: 4502) and Dr Reddy’s Laboratories (BSE: 500124) for example, posted double-digit declines in net profit while others such as Lupin Ltd (NYSE: MYL) saw significant growth as its profits rose more than 40% year-on-year due to strong sales growth in their US market. The shares prices of 11 leading Asian pharmaceutical companies posted average gains of approximately 22% over the six-month period under review from September 4, 2012, to February 26, 2013. Ten out of the 11 companies assessed by Mergent saw their share prices rise over the period, with Dainippon Sumitomo Pharma’s stock price rising the most at nearly 58%. In the past six months, pharmaceutical merger and acquisition activity in the region somewhat slowed down, compared to the strong level of merger and acquisition activity (M&A) seen in the first half of 2012.